Moffitt Study supported by $10 Million Grant from Pfizer

January 29, 2077

Tampa, FL  – Researchers are setting out to discover why so few people with cancer enroll in trials of experimental medicines.

Clinical trials are essential to finding new and effective treatments for cancer but participation is especially low in minorities and the elderly, both highly represented in Florida. To improve trial participation, it is important to understand how people learn about trials and how doctors discuss them.

H. Lee Moffitt Cancer Center & Research Institute, in partnership with Pfizer, will conduct a collaborative three-year research project consisting of two distinct quality of care projects. The research is funded by a $10 million grant from Pfizer. The study will be directed by Paul Jacobsen, Ph.D., program leader of the Health Outcomes and Behavior Program.

The first project will review the records of patients in Florida with breast, colon and lung cancer to determine the level of adherence to clinical practice guidelines as established by the National Comprehensive Cancer Network (NCCN). The second will review records of newly diagnosed metastatic cancer patients to evaluate access to and participation in clinical trials.

“With this support, Moffitt takes a big step forward in its goal of working with our community partners to improve the quality of care patients receive,” said Jacobsen. “The support will also help us find ways to increase patient participation in clinical trials, which is essential for development of more effective cancer therapies.”

            The two projects will be conducted both at Moffitt and at selected sites throughout Moffitt’s extensive regional affiliate network of hospitals and physicians. Both of these quality of care projects further the mission of Moffitt’s Total Cancer Care (TCC) Project, which is designed to bring evidence-based medicine to patients in their own communities.

After the initial stage, the goal is to gather patient information prospectively using state-of-the-art technology to follow patients longitudinally for health outcomes analysis.

            “Quality cancer care with an emphasis on trial participation is our goal at Center for Cancer Care and Research,” said Dr. Fred Schreiber, Hematology-Oncology at Watson Clinic in Lakeland. “Through these efforts we hope to bring new technologies to the community and advance care. We look forward to working with Moffitt and Pfizer in developing projects that will lead to new and effective treatments.”

Data from the study would be used to improve access to clinical trials and to find ways to help people make informed decisions about participating in clinical trials.

            “This partnership with the Moffitt Cancer Center promises to deliver important new information that will help patients and their doctors,”  said Dr. Chuck Baum, vice president of Oncology Development for Pfizer. “In cancer, the medical need remains enormous so this is one of Pfizer’s most important therapeutic areas. Our priorities are to develop new medicines and find better ways to deliver this innovation to patients in need.”


About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida on the University of South Florida campus, H. Lee Moffitt Cancer Center & Research Institute ( is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of America’s Best Hospitals for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.